51
|
Welling KL, Taaning E, Lund BV, Rosenkvist J, Heslet L. Post-transfusion purpura (PTP) and disseminated intravascular coagulation (DIC). Eur J Haematol 2003; 71:68-71. [PMID: 12801301 DOI: 10.1034/j.1600-0609.2003.00092.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
A 47-yr-old female with acute pancreatitis received four units of fresh frozen plasma because of subtle signs of disseminated intravascular coagulation (DIC). Seven days later, she developed severe thrombocytopenia. Serological studies demonstrated antibodies against HPA-1a together with pan-reactive antibodies against platelet glycoproteins (GPIIb-IIIa, GPIb-IX and GPIa-IIa), which was consistent with the diagnosis of PTP. The patient was treated with platelet transfusions, corticosteroids and intravenous immunoglobulin (IVIG) without permanent beneficial effect. After treatment with plasma exchange the platelet count increased to normal values.
Collapse
|
52
|
D'Arena G, Luigiavigliotti M, Coccaro M, Iodice G, Tartarone A, Matera R, Di Renzo N. Late and long-lasting response in an adult chronic idiopathic thrombocytopenic purpura after extended course of rituximab. Leuk Lymphoma 2003; 44:561-2. [PMID: 12688335 DOI: 10.1080/1042819021000055020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
53
|
Ambriz-Fernández R, Martínez-Murillo C, Quintana-González S, Collazo-Jaloma J, Bautista-Juárez J. Fc receptor blockade in patients with refractory chronic immune thrombocytopenic purpura with anti-D IgG. Arch Med Res 2002; 33:536-40. [PMID: 12505098 DOI: 10.1016/s0188-4409(02)00412-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
BACKGROUND This is an evaluation of the treatment of 63 patients with chronic immune thrombocytopenic purpura (54 splenectomized and nine nonsplenectomized) with weekly doses of anti-D (IgG)-coated red blood cells (RBCs). METHODS All patients were given one 5-15 microg/kg/dose of intravenous (i.v.) anti-D (IgG)-coated RBCs per week (average of 300 microg/dose/week) for a median 3-month period (3-6 months). Treatment modality was evaluated on a weekly basis by platelet counts, measuring of hemoglobin levels, and performance of Coombs tests. RESULTS All patients presented a clinical response. Fifty-two patients (82.5%) increased their platelet count (PC) and 45 (69.8%) increased their PC >50 x 10(9)/L. In 34 cases, response was sustained. Six of nine nonsplenectomized patients (67%) increased PC, thus avoiding splenectomy; four patients attained a stable complete response (CR). Similar platelet responses were observed in homozygous and heterozygous Rh (D)-positive patients (Rh/Hr phenotypes). Currently, after >10 years, 43 patients present a now permanent complete response with platelet count >50 x 10(9)/L. Ten patients subsequently decreased their platelet count, although they were able to attain CR after receiving six doses of anti-D (IgG)-coated RBCs. CONCLUSIONS Based on our study of Fc receptor blockade treatment with anti-D (IgG)-coated RBCs with the most difficult cases of ITP, which resulted in a 69.8% successful response rate, we concluded that weekly prescription of anti-D (IgG)-coated RBCs is an effective approach to treating chronic refractory ITP.
Collapse
|
54
|
Deodhar A, Allen E, Daoud K, Wahba I. Vasculitis secondary to staphylococcal Protein A immunoadsorption (Prosorba column) treatment in rheumatoid arthritis. Semin Arthritis Rheum 2002; 32:3-9. [PMID: 12219317 DOI: 10.1053/sarh.2002.33723] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVE Vasculitis is a rare complication of immunoadsorption treatment with staphylococcal Protein A (Prosorba column). The prevalence, clinical characteristics, pathophysiology, treatment, and outcome of vasculitis secondary to immunoadsorption treatment is not known. METHODS The authors describe a 57-year-old woman with rheumatoid arthritis (RA) resistant to methotrexate and etanercept, who developed severe leukocytoclastic vasculitis after the 9th weekly treatment with Prosorba column. She developed rapidly progressive crescentic glomerulonephritis and required treatment with cyclophosphamide and high-dose prednisone. Subsequently, renal function stabilized and RA remitted. Through the literature search and by reviewing information submitted to Cypress Biosciences Inc (manufacturer of Prosorba columns), available world literature on vasculitis secondary to Prosorba column treatment was compiled. RESULTS Immune complex deposition of staphylococcal Protein A (SPA)/SPA antibodies in the glomeruli precipitated the renal disease in our patient. Twenty cases of vasculitis (calculated prevalence, 1 per 400), 5 with internal organ involvement, have been reported in patients treated with Prosorba column for thrombocytopenic purpura. Seven RA patients treated with Prosorba column developed vasculitis (prevalence, 7 per 400), 3 with internal organ involvement. CONCLUSIONS Vasculitis secondary to staphylococcal Protein A immunoadsorption therapy occurs rarely and appears to be related to development of SPA/SPA antibody immune complexes. Rheumatologists should be aware of this potentially serious complication of the Prosorba column treatment for RA.
Collapse
MESH Headings
- Antibodies, Bacterial/analysis
- Antigen-Antibody Complex/analysis
- Arthritis, Rheumatoid/complications
- Arthritis, Rheumatoid/pathology
- Arthritis, Rheumatoid/therapy
- Female
- Glomerulonephritis/etiology
- Glomerulonephritis/pathology
- Humans
- Immunosorbent Techniques/adverse effects
- Kidney Glomerulus/blood supply
- Kidney Glomerulus/drug effects
- Kidney Glomerulus/immunology
- Middle Aged
- Plasmapheresis
- Purpura, Thrombocytopenic/complications
- Purpura, Thrombocytopenic/therapy
- Staphylococcal Protein A/adverse effects
- Staphylococcal Protein A/immunology
- Vasculitis, Leukocytoclastic, Cutaneous/etiology
- Vasculitis, Leukocytoclastic, Cutaneous/pathology
Collapse
|
55
|
Duclos-Vallée JC. [Treatment of hepatitis C virus associated extrahepatic manifestations]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 2002; 26 Spec No 2:B76-81. [PMID: 12180311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
|
56
|
Cosmai EM, Puzis L, Tsai HM, Lian ECY. Thrombocytopenic purpura and cardiomyopathy in pregnancy reversed by combined plasma exchange and infusion. Eur J Haematol 2002; 68:239-42. [PMID: 12071941 DOI: 10.1034/j.1600-0609.2002.01605.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Thrombocytopenia and hemolytic anemia have been seen with thrombotic thrombocytopenic purpura (TTP), HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets), and hemolytic uremic syndrome (HUS). Differentiating between TTP, HUS, and HELLP syndrome is often difficult. Coexistence of TTP and HELLP is possible. Cardiomyopathy occurring in pregnancy can be idiopathic or associated with TTP. We describe a previously healthy woman who developed thrombocytopenia and hemolysis at 34 wk gestation. The patient underwent delivery after transfusion with platelets and RBCs. The suspicion of TTP was raised, and plasma exchange was begun by the third hospital day. On the seventh day of treatment, the patient developed shortness of breath, and an echocardiogram showed global hypokinesis with an ejection fraction of 25%. Plasma infusion, one unit q 4 h, was initiated in addition to the daily plasma exchange. The patient improved and her ejection fraction normalized. Plasma exchange and infusion and corticosteroids were gradually tapered off. von Willebrand factor (vWF) protease activity in the plasma upon transfer was completely deficient with the presence of inhibitor. This case illustrates that vWF protease assay and detection of inhibitor can be used for the diagnosis of TTP during pregnancy; and a severe cardiomyopathy in TTP can be reversed rapidly with combined plasma exchange and infusion.
Collapse
|
57
|
Abstract
In summary, use of plasmapheresis has changed in recent years given advances in medical technology that have allowed a wider clinical application in the critical care setting. Membrane filtration technology has provided an alternative to centrifugation that can be easily applied in intensive care units. Use of plasmapheresis has also changed in recent years reflecting the availability of evidence largely obtained from controlled prospective studies. However, the clinical efficacy of plasmapheresis for many acute renal conditions is still controversial. Plasmapheresis appears to be a useful adjunct to conventional therapy in the treatment of anti-GBM nephritis, severe dialysis-dependent forms of pauciimmune RPGN, cryoglobulinemia, and HUS-TTP. Reported data also suggest a possible benefit of plasmapheresis in patients with myeloma cast nephropathy, sepsis, and poisoning/overdose, but the case for plasmapheresis in these disorders is largely unproven and the reported evidence insufficient to recommend its use outside research settings. In contrast, data from controlled trials do not support a role for plasmapheresis in immune complex-mediated RPGN, such as lupus nephritis, and acute allograft rejection. The more widespread application of prospective, randomized, controlled clinical trials should help to better define the value of plasmapheresis for treatment of acute renal diseases.
Collapse
|
58
|
Ergas D, Tsimanis A, Shtalrid M, Duskin C, Berrebi A. T-gamma large granular lymphocyte leukemia associated with amegakaryocytic thrombocytopenic purpura, Sjögren's syndrome, and polyglandular autoimmune syndrome type II, with subsequent development of pure red cell aplasia. Am J Hematol 2002; 69:132-4. [PMID: 11835350 DOI: 10.1002/ajh.10024] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We present a female patient with T-gamma LGL leukemia, who was followed for the last 20 years. Over these years she developed several autoimmune disorders, including Sjögren's syndrome, Hashimoto's thyroiditis, premature ovarian failure (compatible with type II autoimmune polyglandular syndrome), amegakaryocytic thrombocytopenic purpura, and finally pure red cell aplasia. PCR analysis confirmed rearrangement for TCR gamma. This case emphasizes the complex association of LGL leukemia with autoimmune disorders.
Collapse
MESH Headings
- Adult
- Blood Transfusion
- Female
- Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor/genetics
- Humans
- Leukemia, T-Cell/blood
- Leukemia, T-Cell/immunology
- Leukemia, T-Cell/therapy
- Polyendocrinopathies, Autoimmune/blood
- Polyendocrinopathies, Autoimmune/immunology
- Polyendocrinopathies, Autoimmune/therapy
- Polymerase Chain Reaction
- Pregnancy
- Pregnancy Complications
- Primary Ovarian Insufficiency/immunology
- Purpura, Thrombocytopenic/blood
- Purpura, Thrombocytopenic/immunology
- Purpura, Thrombocytopenic/therapy
- Red-Cell Aplasia, Pure/blood
- Red-Cell Aplasia, Pure/immunology
- Red-Cell Aplasia, Pure/therapy
- Sjogren's Syndrome/blood
- Sjogren's Syndrome/immunology
- Sjogren's Syndrome/therapy
- Thyroiditis, Autoimmune/immunology
Collapse
|
59
|
Szkodny E, Sikora J, Bakon I, Zietek J. [Pregnancy and delivery in women with thrombocytopenia]. Ginekol Pol 2001; 72:1296-9. [PMID: 11883267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023] Open
Abstract
Maternal immune thrombocytopenia is a frequent finding in pregnancy and is most commonly asymptomatic and clinically benign. 8 pregnant women with thrombocytopenia between January 1995 and December 2000, in Clinic of Obstetrics and Gynecology in Katowice-Ligota, were evaluated. 7 patients had idiopathic thrombocytopenia purpura and one (31 years old) had cirrhosis, splenomegaly, thrombocytopenia and elevated liver enzymes. 6 cases was steroid-treated with initial platelet count 4,000 per cubic millimeter to 115,000 per cubic millimeter after treatment. Alloimmune thrombocytopenia is a serious fetal disorder, resulting from platelet-antigen incompatibility between the mother and fetus. Among all newborns only one had thrombocytopenia, platelet count 45,000 per cubic millimeter, without neonatal intracranial hemorrhage. 6 women had cesarean section and 2 patients delivered naturally.
Collapse
|
60
|
George JN, Vesely SK. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and treatment. Cleve Clin J Med 2001; 68:857-8, 860, 863-4 passim. [PMID: 11596624 DOI: 10.3949/ccjm.68.10.857] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Prompt recognition of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) and initiation of plasma exchange treatment is critical as it substantially decreases mortality. Nevertheless, death and long-term complications remain common. The recent relaxation of diagnostic criteria has dramatically increased the number of patients treated for clinically suspected TTP-HUS.
Collapse
|
61
|
Leung AY, Chim CS, Kwong YL, Lie AK, Au WY, Liang R. Clinicopathologic and prognostic features of chronic idiopathic thrombocytopenic purpura in adult Chinese patients: an analysis of 220 cases. Ann Hematol 2001; 80:384-6. [PMID: 11529462 DOI: 10.1007/s002770100306] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
To determine the clinicopathologic and prognostic features of chronic idiopathic thrombocytopenic purpura (ITP) in adult Chinese patients, we conducted a retrospective analysis of 220 patients seen at a single center over a 40-year period. The female-to-male ratio was 4:1, with a mean age of 42.1 +/- 1.3 years, a mean platelet count of 33.7 +/- 2.3x10(9)/l, and a mean follow-up of 116 +/- 7 months. Initial steroid treatment was required in 142 patients, 67 of whom (47.2%) achieved complete remission (CR). At 470 months, 46% patients remained in CR. Splenectomy was performed in 37 patients: in 23 patients due to primary steroid refractoriness and in 7 patients due to disease relapse following initial CR with steroids. In seven patients, data on response to steroids prior to splenectomy were not available. Splenectomy for steroid nonresponders resulted in an inferior CR rate (13 of 23, 56%) as compared with that for relapses after steroid treatment (7 of 7, 100%) (P<0.05). Compared with patients with negative antinuclear antibody (ANA), those who were ANA positive had similar responses to steroids, but significantly shorter remission after splenectomy (P<0.01). In conclusion, Chinese patients with ITP could maintain long-term remission after steroid therapy and splenectomy. In addition, primary steroid refractoriness and positive ANA were bad prognostic factors of the subsequent response to splenectomy.
Collapse
|
62
|
|
63
|
Salim R, Nachum Z, Shalev E. [Immune thrombocytopenic purpura in pregnancy]. HAREFUAH 2001; 140:236-42. [PMID: 11303352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
64
|
Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001; 112:1076-8. [PMID: 11298610 DOI: 10.1046/j.1365-2141.2001.02627.x] [Citation(s) in RCA: 100] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Treatment with 75 microg/kg/d intravenous (i.v.) anti-D was compared with 50 microg/kg/d in a prospective randomized study of 27 RhD-positive, human immunodeficiency virus-negative, adult, acute, non-splenectomized patients with immune thrombocytopenic purpura (ITP) and platelet counts < or = 30 x 109/l. The higher dose resulted in greater median d 1 (43 x 109/l vs. 7.5 x 109/l; P = 0.012) and d 7 (153 x 109/l vs. 64.5 x 109/l; P = 0.001) platelet increases despite no greater haemoglobin decrease. Children with acute ITP receiving 75 microg/kg/d had overnight platelet increases in seven out of nine cases. The duration of effect at the 75 microg/kg/d dose was 46 d vs. 21 d (P = 0.03). Adverse events were mild to moderate and ameliorated with prednisone and acetaminophen premedication.
Collapse
|
65
|
McCrae KR, Bussel JB, Mannucci PM, Remuzzi G, Cines DB. Platelets: an update on diagnosis and management of thrombocytopenic disorders. HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM 2001; 2001:282-305. [PMID: 11722989 DOI: 10.1182/asheducation-2001.1.282] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Thrombocytopenia in the pregnant patient may result from a number of causes, most of which involve either immune-mediated platelet destruction or platelet consumption. Many of these disorders share clinical and laboratory features, making accurate diagnosis difficult. Moreover, uterine evacuation is indicated in the therapy of some disorders, while in others alternative interventions may allow the pregnancy to be carried to term. These and other issues are discussed as part of a comprehensive review of the differential diagnosis and management of thrombocytopenia in pregnancy. The term "refractory ITP" is used with reference to two distinct groups of patients: 1) patients in whom the platelet count cannot be easily increased, including those who are poorly responsive to initial single agent treatment, and 2) those with persistent thrombocytopenia despite the use of conventional therapies. An approach to management of the former group will be presented, followed by a discussion of patients with chronic refractory ITP. The latter will include presentation of new data on the role of Helicobacter pylori in ITP and whether its treatment ameliorates thrombocytopenia, as well as the use of rituximab and other modalities. Thrombotic microangiopathies such as thrombotic thrombocytopenic purpura (TTP) are rare, but life threatening causes of thrombocytopenia. Ultra-large multimers of von Willebrand factor (vWF) aggregate platelets intravascularly, and congenital or immune-mediated deficiencies of a metalloprotease that cleaves these ultra-large multimers may cause TTP. However, little information exists concerning the behavior of this protease in other physiological and pathological conditions. Levels of this protease have now been measured in healthy individuals of different ages, full-term newborns, pregnant women and a patients with variety of pathologic conditions, and these data will be reviewed herein. Heparin-induced thrombocytopenia/thrombosis (HIT/T) remains the most common antibody-mediated, drug-induced thrombocytopenic disorder, and a leading cause of morbidity and mortality. Based on clinical correlations and murine models, there is increasing evidence that antibodies to complexes between platelet factor 4 (PF4) and heparin cause HIT/T, and the molecular composition of the relevant antigen has also become better defined. However, the introduction of sensitive ELISAs to measure anti-PF4/heparin antibodies has complicated diagnosis in some settings in which the incidence of such antibodies in unaffected patients exceeds the incidence of the disease. In addition, the FDA approval of Lepirudin and Argatroban has expanded the repertoire of agents available for therapy of HIT/T and may change the approach to management of asymptomatic patients with thrombocytopenia. However, the optimal use of these drugs in commonly encountered settings remains in evolution, and a need for alternative approaches to prevention and treatment is evident.
Collapse
|
66
|
Ohhashi J, Miyamoto M, Ishikawa S, Hashizume Y, Nishido T, Matsuyama K, Morino K, Miyazaki Y. Crescentic glomerulonephritis with positive antineutrophil cytoplasmic autoantibody specific for myeloperoxidase associated with autoimmune hemolytic anemia and thrombocytopenic purpura. Intern Med 2000; 39:650-4. [PMID: 10939540 DOI: 10.2169/internalmedicine.39.650] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A 41-year-old woman was admitted to the hospital with severe uremia, hemolytic anemia, and thrombocytopenic purpura. Emergency hemodialysis with plasmapheresis was started in view of consideration of hemolytic uremic syndrome (HUS), which resulted in improvement of renal function and platelet count. Positive antineutrophil cytoplasmic autoantibody specific for myeloperoxidase (MPO-ANCA) suggested crescentic glomerulonephritis, which was pathologically evidenced by renal biopsy. The diagnosis of MPO-ANCA associated crescentic glomerulonephritis with autoimmune hemolytic anemia (AIHA) and thrombocytopenic purpura were confirmed. Three courses of steroid pulse therapy with heparin were successfully performed, followed by oral prednisolone and warfarin. Such a case has not been previously reported to our knowledge.
Collapse
|
67
|
MESH Headings
- Adult
- Anemia, Aplastic/therapy
- Anemia, Sickle Cell/physiopathology
- Anemia, Sickle Cell/therapy
- Antibodies, Anti-Idiotypic/immunology
- Antigens, Human Platelet/immunology
- Autoantibodies/immunology
- Autoimmune Diseases/immunology
- Autoimmune Diseases/therapy
- Babesiosis/therapy
- Blood Coagulation Disorders/immunology
- Blood Coagulation Disorders/therapy
- Blood Coagulation Factors/immunology
- Blood Component Removal
- Blood Group Incompatibility/therapy
- Blood Viscosity
- Bone Marrow Transplantation/immunology
- Child
- Clinical Trials as Topic
- Combined Modality Therapy
- Erythroblastosis, Fetal/therapy
- Hematologic Diseases/therapy
- Hemochromatosis/drug therapy
- Hemochromatosis/therapy
- Humans
- Infant, Newborn
- Kidney Diseases/etiology
- Kidney Diseases/therapy
- Leukocytosis/drug therapy
- Leukocytosis/radiotherapy
- Leukocytosis/therapy
- Lymphoma, T-Cell, Cutaneous/drug therapy
- Lymphoma, T-Cell, Cutaneous/therapy
- Malaria/drug therapy
- Malaria/therapy
- Multiple Myeloma/complications
- Multiple Myeloma/therapy
- Neoplasms/therapy
- Paraproteinemias/physiopathology
- Paraproteinemias/therapy
- Photopheresis
- Plasma Exchange
- Polycythemia/drug therapy
- Polycythemia/therapy
- Polycythemia Vera/drug therapy
- Polycythemia Vera/therapy
- Purpura, Thrombocytopenic/drug therapy
- Purpura, Thrombocytopenic/etiology
- Purpura, Thrombocytopenic/therapy
- Purpura, Thrombotic Thrombocytopenic/therapy
- Randomized Controlled Trials as Topic
- Red-Cell Aplasia, Pure/therapy
- Thrombocytosis/drug therapy
- Thrombocytosis/therapy
- Transfusion Reaction
Collapse
|
68
|
Bandarenko N, Brecher ME. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher 2000; 13:133-41. [PMID: 9828024 DOI: 10.1002/(sici)1098-1101(1998)13:3<133::aid-jca7>3.0.co;2-z] [Citation(s) in RCA: 109] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Thrombotic thrombocytopenic purpura (TTP) remains enigmatic from the perspective of its etiology, pathophysiology, and treatment. Once recognized, the accepted standard of care for TTP is daily therapeutic plasma exchange (TPE). However, the diversity in TPE treatment protocols has made comparisons of clinical research between institutions difficult. This study strived to assess the current practice of TPE in order to provide direction for prospective controlled clinical trials. Twenty large apheresis centers within the United States comprising the US TTP ASG responded to a survey to establish the current status of TPE in TTP. A retrospective analysis from data provided by 14 of 20 centers included 115 initial presentations of primary TTP with an overall mortality rate of 10% and relapse rate of 37%. The majority of deaths (58%) occurred within 48 hours of presentation. Variation in therapeutic targets (platelet count [plt] and serum LDH) and the number of plasma volumes exchanged per procedure did not affect the relapse rate. Initial plt and LDH were not predictive of mortality. Response, relapse, and mortality rates with the combination of 5% albumin for the initial 50% of TPE followed by plasma for the final 50% of TPE as replacement were comparable or possibly better than plasma-only replacement strategies. Forty percent of centers routinely used a TPE taper; however, there was no statistical difference in relapse rates comparing the taper and non-taper sub-groups. By controlling for adjunctive modalities such as steroids and anti-platelet agents, it is hoped that future prospective clinical trials may optimize the role of TPE in TTP, minimize patient exposure to blood products and procedures, shorten the clinical course of TTP, and reduce mortality.
Collapse
|
69
|
Sandler SG, Novak SC, Roland B. The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin. Am J Hematol 2000; 63:156-8. [PMID: 10679807 DOI: 10.1002/(sici)1096-8652(200003)63:3<156::aid-ajh9>3.0.co;2-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Multiple factors, including efficacy, toxicity and cost, may influence the decision to treat immune thrombocytopenic purpura (ITP) with intravenous immune globulin (IVIG) or intravenous Rho (D) immune globulin (IV RhIG). We conducted a survey of 50 hospitals in 31 states to determine the costs for treating ITP using conventional doses for IVIG or IV RhIG, based on package insert recommendations. The average cost for a dose of IVIG ($2,771) was 71.7% ($1,157) more than that for a dose of IV RhIG ($1,614). In the absence of clearly defined differences in clinical outcomes when treating ITP with IVIG or IV RhIG, the difference in cost may be an important factor in selecting the treatment.
Collapse
|
70
|
Gómez Reino JJ, Maceiras Pan F. [Thrombocytopenia and lupus]. ANALES DE MEDICINA INTERNA (MADRID, SPAIN : 1984) 1999; 16:609-10. [PMID: 10686710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
|
71
|
Marmont AM. Immune ablation and stem cell transplantation for severe Evans syndrome and refractory thrombocytopenic purpura. Bone Marrow Transplant 1999; 23:1215-6. [PMID: 10414905 DOI: 10.1038/sj.bmt.1701823] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
72
|
Zafar T, Yasin F, Anwar M, Saleem M. Acquired amegakaryocytic thrombocytopenic purpura (AATP): a hospital based study. J PAK MED ASSOC 1999; 49:114-7. [PMID: 10555427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
OBJECTIVE To determine the frequency of Acquired Amegakaryocytic Thrombocytopenic Purpura (AATT), possible aetiology, course and prognosis. DESIGN Retrospectively diagnosed patients, treated and followed prospectively. SETTING Department of Haematology, Armed Forces Institute of Pathology, Rawalpindi. SUBJECTS One hundred twenty patients with thrombocytopenic purpura. MAIN OUTCOME MEASURES Response to treatment and course of disease. RESULTS Out of 22 patients 2 died of cerebral haemorrhage, one transformed to Myelodysplastic Syndrome (MDS), one transformed to Acute Myeloid Levkaenia (AML). None is transfusion independent. CONCLUSION AATT is not an infrequent disorder. It shows poor response to all available therapeutic modalities and has a potential for transformation into Myelodysplasia and acute myeloid leukaemia.
Collapse
|
73
|
Shimano S, Murayama K, Yokohama A, Murata N, Tsuchiya J. [Marked thrombocytopenia after high-dose intravenous gamma globulin in a pregnant woman with idiopathic thrombocytopenic purpura]. [RINSHO KETSUEKI] THE JAPANESE JOURNAL OF CLINICAL HEMATOLOGY 1999; 40:318-23. [PMID: 10355141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
A 35-year-old pregnant woman had thrombocytopenia with a platelet count of 6.3 x 10(4)/microliter. After her third normal delivery, peripheral blood studies revealed that the patient had a normal Hb concentration and leukocyte count, with mild thrombocytopenia. A diagnosis of idiopathic thrombocytopenic purpura (ITP) was made based on the high megakaryocyte count of 338/microliter and PAIgG of 40.8 ng/10(7) cells in January 1995. The patient was followed without treatment. She was 9 weeks pregnant on June 7, 1996, and desired an abortion. Her platelet count was 6.3 x 10(4)/microliter, leukocyte count 8,600/microliter, and Hb 13.7 g/dl at the time. She was given high-dose intravenous gammaglobulin (Globenin-I) at 400 mg/kg/day for 5 consecutive days. The platelet count was found to have decreased markedly, to 0.9 x 10(4)/microliter on June 11. The percentage reduction in the Hb concentration, leukocyte count, and platelet count after gammaglobulin treatment was 11.7%, 46.6%, and 85.8%, respectively. The PAIgG titer had increased to 181.2 ng/10(7) cells on June 17, but hypergammaglobulinemia was suspected. The patient was started on prednisolone on June 24, and an abortion was performed on July 29. The mechanism of thrombocytopenia after infusion of Globenin-I was unknown. We suspect that Globenin-I treated with polyethylene glycol was one of the possible causes of myelosuppression in this case.
Collapse
|
74
|
Sturgill MG, Drachtman RA, Ettinger AG, Rubin J, Ettinger LJ. The influence of Epstein-Barr virus seropositivity on the efficacy of intravenous immune globulin in children with immune thrombocytopenic purpura. Clin Pediatr (Phila) 1999; 38:171-3. [PMID: 10349084 DOI: 10.1177/000992289903800309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
75
|
Martinez Lagares F, Fernandez Fuertes F, Hernandez Cabrero T, Bosch Benitez J, Gonzalez San Miguel J, Martín Y, Tapia Martín M, Muñíz Montero F, Viejo Llorente A, Givica Perez A, Díaz Cremades JM. Complete splenic embolization in the treatment of immune thrombocytopenic purpura. Br J Haematol 1998; 103:894-5. [PMID: 9858253 DOI: 10.1046/j.1365-2141.1998.01120.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|